The single thing that separates a good GLP-1 telehealth experience from a frustrating one is pharmacy transparency. Not the slickest app. Not the celebrity endorsement. Knowing what’s in your vial, who made it, and whether a real physician will actually review your case.
That standard is the thread running through this list.
#1 HealthRX
Start here if cash price and verified sourcing both matter to you. HealthRX keeps compounded semaglutide under $100 a month and compounded tirzepatide around $149, which undercuts most telehealth competitors charging $199 or more for the same category of medication. Overnight shipping to all fifty states is included, no membership tier required.
What earns it the top slot is specificity. The compounding pharmacy is Manifest Pharmacy in Greer, South Carolina, a 503A facility operating under USP-797 standards with lot-level tracking from bench to doorstep. That’s the kind of supply-chain detail most telehealth brands skip entirely. HealthRX also carries LegitScript certification (cert 50087439), and physician review of your online health assessment runs roughly 24 hours. Fast, transparent, and cheaper than almost anything comparable.
The referenced clinical data comes from published trials. Tirzepatide produced around 21% body-weight reduction at 72 weeks in SURMOUNT-1. Semaglutide showed approximately 15% at 68 weeks in STEP 1. These are trial figures, not HealthRX’s own outcomes data, and compounded medications are not FDA-approved. Worth understanding before you start.
#2 FormBlends
Different use case, genuine value. FormBlends runs a compounded GLP-1 program with physician oversight and dispenses through an FDA-registered 503A compounding pharmacy. What sets it apart is that it publishes actual purity testing per product. We’re talking HPLC purity percentages, mass spec identity confirmation, and endotoxin sterility results with named numbers, not just a vague “third-party tested” badge.
Per-vial pricing is higher than HealthRX (semaglutide around $299, tirzepatide around $349), so it’s not the value pick. But if you want documented batch-level purity data, or if you’re also interested in peptides beyond GLP-1s (recovery, longevity, cognitive), FormBlends carries a broader catalog under the same clinician model. Shipping reaches 47 states. For someone who wants a single provider covering weight loss and other peptide protocols, this is the natural choice.
#3 Mochi Health
Mochi specifically hires board-certified obesity-medicine physicians, which is not standard across telehealth. Monthly costs typically land near $99 for semaglutide and $199 for tirzepatide. The monitoring cadence is more involved than budget platforms, which suits people who want their prescriber to actually track progress.
#4 Hims & Hers
After a settlement with Novo Nordisk in March 2026, Hims exited compounded GLP-1s and shifted to branded medications. Injectable Wegovy lists at roughly $299 a month through the platform, Zepbound around $399. For people with insurance and a savings card, out-of-pocket can drop to near zero. Big audience, polished experience, limited flexibility on formulation.
#5 Ro / Ro Body
Ro’s membership starts at $39 for the first month, then $74 to $149 monthly, with medications billed separately. The platform has a dedicated prior-authorization team that works insurance on your behalf for branded meds. Good option for anyone whose employer plan might actually cover Wegovy or Zepbound and who wants help with the paperwork.
#6 Henry Meds
Cash-pay compounded GLP-1s with unusually fast shipping (24 to 72 hours). First-month pricing typically falls between $179 and $249. Monitoring is lighter than Mochi, which is either a feature or a drawback depending on how much clinical hand-holding you want.
#7 PlushCare
Monthly membership is $19.99, one of the lowest platform fees on this list. PlushCare focuses on branded medications and accepts insurance, with same-day appointment availability in many states. It functions more like a traditional telehealth clinic than a GLP-1-specific program.
#8 Found
Found charges around $99 a month for the platform and adds medication costs on top. Coaching is included. It positions itself as a behavior-change program that happens to prescribe GLP-1s, not simply a prescription vending service.
#9 Form Health
The premium end of this list. Form Health pairs an MD with a registered dietitian, charges roughly $299 a month for the program (labs and meds separate), and targets people who want intensive clinical support. The price reflects real professional time, not just a quick async assessment.
#10 Sesame
Sesame works differently from every other provider here. It’s a marketplace where you book directly with independent clinicians, from about $59 a month on an annual plan, with medications priced and filled separately. No proprietary drug program, no package deals. Just a lower-friction way to access a licensed prescriber.
How to Actually Choose
Price alone is a bad filter. Figure out whether you want compounded or branded medication first, because that splits the field immediately. After the FDA warning letters sent to 30-plus telehealth and compounding firms in early 2026, pharmacy sourcing became a real differentiator, not just marketing language. A named, 503A-certified pharmacy with documented testing is worth more than a vague supplier.
For most cash-pay patients who want compounded GLP-1s at a low entry price with clear pharmacy credentials, HealthRX covers the basics well. Patients who prioritize published purity data or want peptide options beyond weight loss should look at FormBlends, accepting the higher cost. Patients with good insurance and no compounding preference should start with Ro or PlushCare and let prior auth do the work.
Common Questions
Does it matter which 503A pharmacy a telehealth provider uses?
Yes, significantly. A named 503A facility operating under USP-797 standards gives you lot-level traceability and sterility documentation. Providers that list only “FDA-registered pharmacy” without naming the facility or sharing batch testing results give you no way to verify what you’re actually injecting. HealthRX names Manifest Pharmacy in Greer, South Carolina. That specificity is the benchmark.
Why is FormBlends more expensive than HealthRX if both use compounded semaglutide?
FormBlends publishes HPLC purity percentages, mass spec identity confirmation, and endotoxin sterility results per batch. That testing infrastructure costs money. At $299 versus under $100, you’re paying for documented purity data and a broader peptide catalog, not a fundamentally different medication. Whether that premium is worth it depends on how much the lab paperwork matters to you personally.
After Hims exited compounded GLP-1s, what does that mean for patients already on their program?
Hims settled with Novo Nordisk in March 2026 and moved to branded medications only. Patients who were on compounded semaglutide through Hims would need to transition to Wegovy at roughly $299 a month through the platform, or switch providers entirely. Anyone still wanting compounded options at lower cost needs a different telehealth company.
Is Mochi Health actually different from budget platforms, or is “obesity-medicine physician” just a marketing label?
The board-certification distinction is real. Obesity medicine is a recognized subspecialty with its own board exam through the American Board of Obesity Medicine. Most telehealth platforms use general practitioners or internists for async prescription review. Mochi’s model involves more active monitoring, which matters if your case involves comorbidities or you want titration guidance beyond a standard protocol.
Can Ro or PlushCare actually get insurance to cover Wegovy or Zepbound, or is that mostly theoretical?
Coverage depends entirely on your specific plan. Ro has a dedicated prior-authorization team, which improves the odds compared to doing it yourself, but employer self-insured plans frequently exclude weight-loss drugs regardless of effort. PlushCare works similarly. Neither platform can guarantee coverage. The realistic expectation is that they handle the paperwork competently, not that approval is certain.
Sources
- FDA MedWatch and warning letters database (2025-2026), FDA.gov
- SURMOUNT-1 trial, Jastreboff et al., *New England Journal of Medicine*, 2022
- STEP 1 trial, Wilding et al., *New England Journal of Medicine*, 2021
- Novo Nordisk settlement announcement, March 9, 2026 (widely reported, AP and Reuters)
- LillyDirect orforglipron pricing announcement, April 2026, Eli Lilly press release
- Individual brand pricing: publicly listed on each provider’s website as of mid-2026
